当前位置:首页 >财报库 > 报告详情

费森尤斯Fresenius(FMS)2024年年度报告「NYSE」(英文版)(417页).pdf

上传人: Y**** 编号:654163 2025-05-21 417页 13.14MB

下载:

1、ANNUAL REPORT 2024Group in figures Table of contentsMedia HubTargets,results,and outlookFresenius is a global healthcare company.Committed to life the health and well-being of patients is Fresenius top priority.For more than 100 years,we have been combining cutting-edge technology with a focus on pa

2、tients,paving the way for the therapies of the future.We save and improve lives and health.We provide access to affordable and innovative medical products and clinical care of the high-est quality.Operating CompaniesFront page2Fresenius|Annual Report 2024Group in figures Table of contentsMedia HubTa

3、rgets,results,and outlook in millions20242023202220212020 Revenue and earningsRevenue 121,52620,307 21,532 19,969 18,476 EBITDA 1,23,6143,319 3,315 3,353 3,042 EBIT 1,22,4892,266 2,190 2,337 2,113 Net income 1,2,31,7491,543 1,729 1,8671,796Depreciation and amortization 1,21,1251,145 1,125 1,016 929

4、Earnings per share in 1,2,33.112.743.083.353.22Cash flow and balance sheetOperating cash flow 12,4472,131 2,031 2,589 2,316 Free cash flow before acquisitions,dividends and lease liabilities 11,6231,1309421,401986Free cash flow after acquisitions,dividends and lease liabilities 11,730188-31838818Cas

5、h conversion rate 11.01.00.90.90.8Total assets43,55045,284 76,400 71,962 66,646 Non-current assets32,10432,764 58,121 54,501 50,874 Equity 420,29019,651 32,218 29,288 26,023 Equity ratio 447%43%42%41%39%Net debt 111,29513,268 13,316 12,650 13,021 Net debt/EBITDA 1,2,53.03.8 3.8 3.6 4.1 Investments 1

6、,61,0351,346 2,015 1,635 1,841 ProfitabilityEBIT margin 1,211.6%11.2%10.2%11.7%11.4%Return on invested capital(ROIC)1,26.2%5.2%5.6%6.2%5.9%Dividend per share in 1.00 70.920.920.88Employees(December 31)1176,486193,865 188,876 185,827 178,140 1 Prior-year figures have been adjusted due to divestments

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据Fresenius 2024年度报告的内容,我总结了以下关键点: 1. Fresenius是一家全球性的医疗保健公司,2024年实现了显著增长,收入达到1215亿欧元,同比增长8%。 2. 该公司通过#FutureFresenius计划实现了业务转型,专注于Fresenius Kabi和Fresenius Helios两大业务板块,实现了更高的盈利能力和现金流。 3. Fresenius Kabi在生物制药、医疗技术和临床营养三大增长领域取得显著进展,特别是在生物仿制药领域。 4. Fresenius Helios作为欧洲领先的私立医院集团,正在通过数字化转型提升医疗服务质量。 5. Fresenius致力于可持续发展,发布了首份可持续发展亮点报告,并计划到2040年实现碳中和。 6. Fresenius的股价在2024年实现了显著增长,全年涨幅约19.5%,市值达到189亿欧元。 7. Fresenius计划在未来几年内继续推动核心业务发展,实现持续的价值创造。
弗雷森尤斯2024年收入增长情况如何? 弗雷森尤斯2024年现金流量表现如何? 弗雷森尤斯2024年可持续发展报告有哪些亮点?
客服
商务合作
小程序
服务号
折叠